Document Detail


Reversal of multidrug resistance by an immunosuppressive agent FK-506.
MedLine Citation:
PMID:  1370765     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
FK-506, a novel immunosuppressive agent, was examined for its reversing effect on multidrug-resistant tumor cells. FK-506 at 3 microM completely reversed the resistance against vincristine (VCR) in vitro in VCR-resistant mouse leukemia P388 cells (P388/VCR). FK-506 also enhanced the cytotoxicity of VCR in Adriamycin(ADM)-resistant human ovarian cancer A2780 cells (AD10) and ADM-resistant human myelogenous leukemia K562 cells (K562/ADM) in vitro. FK-506 was also effective in modulating sensitivity to ADM in AD10 cells in vitro. FK-506 enhanced the chemotherapeutic effect of VCR in P388/VCR-bearing mice. When 20 mg/kg FK-506 was combined with 200 micrograms/kg VCR, a T/C value of 151% was obtained. Under the protocol used in this study, FK-506 was more potent than cyclosporin A (CsA) and verapamil. FK-506 inhibited [3H]azidopine binding to P-glycoprotein efficiently. The binding of VCR to K562/ADM plasma membrane was inhibited by FK-506 as effectively as by CsA. Moreover, the accumulation of VCR in AD10 cells was increased by FK-506 as efficiently as that of CsA and verapamil. These results indicate that FK-506 directly interacts with P-glycoprotein like CsA and verapamil, inhibits the active efflux of vincristine from resistant cells, increases the vincristine accumulation in resistant cells, and thus overcomes multidrug resistance in vitro and in vivo.
Authors:
M Naito; T Oh-hara; A Yamazaki; T Danki; T Tsuruo
Related Documents :
9500455 - Role of glutathione s-transferases in the resistance of human colon cancer cell lines t...
8794885 - Bibw22 bs, potent multidrug resistance-reversing agent, binds directly to p-glycoprotei...
20053435 - The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamm...
9864175 - Efflux of rhodamine from cd56+ cells as a surrogate marker for reversal of p-glycoprote...
20508865 - Decreasing expression of the g1-phase inhibitors, p21cip1 and p16ink4a, promotes divisi...
454605 - The effect of cell excision and microelectrode perforation on membrane resistance measu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  29     ISSN:  0344-5704     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-03-02     Completed Date:  1992-03-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  195-200     Citation Subset:  IM    
Affiliation:
Institute of Applied Microbiology, University of Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Death / drug effects
Cell Division / drug effects
Doxorubicin / administration & dosage,  pharmacology*
Drug Resistance / genetics*
Drug Synergism
Female
Humans
Leukemia
Leukemia P388 / drug therapy
Membrane Glycoproteins / antagonists & inhibitors
Ovarian Neoplasms
P-Glycoprotein
Tacrolimus / administration & dosage,  pharmacology*
Tumor Cells, Cultured / drug effects*,  metabolism
Vincristine / administration & dosage,  pharmacology*
Chemical
Reg. No./Substance:
0/Membrane Glycoproteins; 0/P-Glycoprotein; 109581-93-3/Tacrolimus; 23214-92-8/Doxorubicin; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Splenic and inguinal lymph node T cells of aged mice respond differently to polyclonal and antigen-s...
Next Document:  Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antin...